In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
In the latest session, Myriad Genetics, Inc (NASDAQ: MYGN) closed at $6.48 down -1.07% from its previous closing price of $6.55. In other words, the price has decreased by -$1.07 from its previous closing price. On the day, 0.76 million shares were traded. MYGN stock price reached its highest trading level at $6.62 during the session, while it also had its lowest trading level at $6.39.
Ratios:
For a deeper understanding of Myriad Genetics, Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.12 and its Current Ratio is at 2.33. In the meantime, Its Debt-to-Equity ratio is 0.57 whereas as Long-Term Debt/Eq ratio is at 0.55.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MYGN now has a Market Capitalization of 604024896 and an Enterprise Value of 670924928. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.73 while its Price-to-Book (P/B) ratio in mrq is 1.62. Its current Enterprise Value per Revenue stands at 0.813 whereas that against EBITDA is -25.608.
Stock Price History:
The Beta on a monthly basis for MYGN is 1.80, which has changed by -0.5245781 over the last 52 weeks, in comparison to a change of 0.17318606 over the same period for the S&P500. Over the past 52 weeks, MYGN has reached a high of $15.47, while it has fallen to a 52-week low of $3.76. The 50-Day Moving Average of the stock is -9.98%, while the 200-Day Moving Average is calculated to be -1.61%.
Shares Statistics:
For the past three months, MYGN has traded an average of 1.09M shares per day and 1045650 over the past ten days. A total of 93.10M shares are outstanding, with a floating share count of 88.73M. Insiders hold about 4.81% of the company’s shares, while institutions hold 97.85% stake in the company. Shares short for MYGN as of 1765756800 were 8629605 with a Short Ratio of 7.89, compared to 1763078400 on 7694493. Therefore, it implies a Short% of Shares Outstanding of 8629605 and a Short% of Float of 13.01.
Earnings Estimates
The firm’s stock currently is rated by 12.0 analysts. The consensus estimate for the next quarter is -$0.0, with high estimates of $0.02 and low estimates of -$0.04.
Analysts are recommending an EPS of between $0.02 and -$0.01 for the fiscal current year, implying an average EPS of $0.01. EPS for the following year is $0.07, with 12.0 analysts recommending between $0.19 and -$0.03.
Revenue Estimates
A total of 12 analysts believe the company’s revenue will be $207.5M this quarter.It ranges from a high estimate of $211.8M to a low estimate of $204.68M. As of. The current estimate, Myriad Genetics, Inc’s year-ago sales were $210.6MFor the next quarter, 12 analysts are estimating revenue of $209.84M. There is a high estimate of $215.27M for the next quarter, whereas the lowest estimate is $206M.
A total of 12 analysts have provided revenue estimates for MYGN’s current fiscal year. The highest revenue estimate was $826.5M, while the lowest revenue estimate was $819.38M, resulting in an average revenue estimate of $822.14M. In the same quarter a year ago, actual revenue was $837.6MBased on 12 analysts’ estimates, the company’s revenue will be $866.71M in the next fiscal year. The high estimate is $896.3M and the low estimate is $846M.
